Cargando…

Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies

INTRODUCTION: We sought to synthesize published empirical studies that elicited and characterized societal valuations of orphan drugs and the attributes that may drive different valuations for orphan drugs versus other treatments. METHODS: We conducted a systematic literature review (SLR) in MEDLINE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dabbous, Omar, Chachoua, Lylia, Aballéa, Samuel, Sivignon, Marine, Persson, Ulf, Petrou, Stavros, Richardson, Jeff, Simoens, Steven, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898379/ https://www.ncbi.nlm.nih.gov/pubmed/36451072 http://dx.doi.org/10.1007/s12325-022-02359-z

Ejemplares similares

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
por: Dabbous, Monique, et al.
Publicado: (2019)

Why “American Patients First” is likely to raise drug prices outside of the United States
por: Dabbous, Monique, et al.
Publicado: (2019)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement
por: Schlander, Michael, et al.
Publicado: (2016)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
por: Hawken, Natalia, et al.
Publicado: (2017)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Urbanicity mental costs valuation: a review and urban-societal planning consideration
por: D’Acci, Luca S.
Publicado: (2020)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA
por: Aballéa, Samuel, et al.
Publicado: (2013)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Guidance for Demonstrating the Societal Value of new Antibiotics
por: Simoens, Steven, et al.
Publicado: (2021)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Patterns, trends and methodological associations in the measurement and valuation of childhood health utilities
por: Kwon, Joseph, et al.
Publicado: (2019)

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients
por: Muduma, Gorden, et al.
Publicado: (2016)

Pharmaceutical expenditure forecast model to support health policy decision making
por: Rémuzat, Cécile, et al.
Publicado: (2014)

EU pharmaceutical expenditure forecast
por: Urbinati, Duccio, et al.
Publicado: (2014)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

Monetary Valuation of Children’s Cognitive Outcomes in Economic Evaluations from a Societal Perspective: A Review
por: Grosse, Scott D., et al.
Publicado: (2021)

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
por: Simoens, Steven
Publicado: (2022)

Chinese guidelines related to novel coronavirus pneumonia
por: Qiu, Tingting, et al.
Publicado: (2020)

The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs
por: Polek, Hubert, et al.
Publicado: (2023)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

State Dependent Valuation: The Effect of Deprivation on Risk Preferences
por: Levy, Dino J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jg0a420jhjbhua8m8768j5f6dc